If a patient is fit for perioperative chemotherapy, screening their tumor for HER2, EGFR, PD-L1, ERCC1, TUBB3, TS, RCF, TOPOI, and TOPO2A would be a straightforward way to inform the oncologist which proteins in the patient’s tumors are prime targets and which proteins could potentially act as resistance molecules for EC drug options (Figure 1). The gene discussed is ERBB2; the disease is neoplasm.